scholarly journals Evidence for direct methyl transfer in betaine: homocysteine S-methyl-transferase.

1983 ◽  
Vol 258 (21) ◽  
pp. 12790-12792
Author(s):  
W M Awad ◽  
P L Whitney ◽  
W E Skiba ◽  
J H Mangum ◽  
M S Wells
Keyword(s):  
Methyl Transferase ◽  
Methyl Transfer

Die Bedeutung der genetischen Bildgebung für psychiatrische Störungen

2009 ◽  
Vol 6 (04) ◽  
pp. 191-198
Author(s):  
C. Konrad ◽  
A. Krug ◽  
T. Kircher
Keyword(s):  
Neurotrophic Factor ◽  
Binding Protein ◽  
Brain Derived Neurotrophic Factor ◽  
Methyl Transferase ◽  
Psychiatrische Forschung ◽  
Psychiatrische Störungen

ZusammenfassungPsychiatrische Störungen sind zu einem großen Teil erblich beeinflusst. Ein verbessertes Verständnis der molekulargenetischen Grundlagen dieser Erblichkeit ist für Klassifikation, Erforschung der Pathogenese und Therapie bedeutsam. Die Gewinnung neuer Erkenntnisse hängt dabei entscheidend von der Auswahl des untersuchten Phänotyps ab. Die Varianz beobachtbarer Phänotypen wird durch eine Vielzahl unterschiedlicher Einflussfaktoren zu einem geringeren Anteil genetisch beeinflusst als die Varianz von Endophänotypen, die mit Hilfe der strukturellen und funktionellen Bildgebung beobachtet werden können. Wichtige Erkenntnisse aus der genetischen Depressions- und Schizophrenieforschung werden zu diesem Thema zusammengefasst. Der Einfluss von Kandidatengenen auf Erleben und Verhalten sowie auf strukturelle und funktionelle Bildgebungscharakteristika wird dargestellt, u.a. bezüglich des Serotonintransporter-Gens (5HTTLPR), Brain Derived Neurotrophic Factor (BDNF), Catechyl-O-Methyl-Transferase (COMT), Neuregulin1 (NRG1), Dysbindin (dystrobrevin binding protein 1, DTNBP1) und Zinkfinger Protein 804A (ZNF804A). Perspektiven für die psychiatrische Forschung werden diskutiert.

Targeting COVID-19 in Parkinson’s patients: Drugs repurposed.

2020 ◽  
Vol 27 ◽  
Author(s):  
Firoz Anwar ◽  
Salma Naqvi ◽  
Fahad A. Al-Abbasi ◽  
Nauroz Neelofar ◽  
Vikas Kumar ◽  
...  
Keyword(s):  
Day Treatment ◽  
Treatment Options ◽  
Developed Countries ◽  
Methyl Transferase ◽  
Comt Inhibitors ◽  
Mao B ◽  
Pharmacokinetic Properties ◽  
Us Fda ◽  
Approved Drugs ◽  
Fda Approved Drugs

: The last couple of months have witnessed the world in a state of virtual standstill. The SARS-CoV-2 virus has overtaken globe to economic and social lockdown. Many patients with COVID-19 have compromised immunity, especially in an aged population suffering from Parkinson disease (PD). Alteration in dopaminergic neurons or deficiency of dopamine in PD patients is the most common symptoms affecting 1% population above the age of 60 years. The compromised immune system and inflammatory manifestation in PD patients make them an easy target. The most common under trial drugs for COVID-19 are Remdesivir, Favipiravir, Chloroquine and Hydroxychloroquine, Azithromycin along with adjunct drugs like Amantadine with some monoclonal antibodies. : Presently, clinically US FDA approved drugs in PD includes Levodopa, catechol-O-methyl transferase (COMT) inhibitors, (Entacapone and Tolcapone), Dopamine agonists (Bromocriptine, Ropinirole, Pramipexole, and Rotigotine), Monoamine oxidase B (MAO-B) inhibitors (Selegiline and Rasagiline), Amantadine and Antimuscarinic drugs. The drugs have established mechanism of action on PD patients with known pharmacodynamics and pharmacokinetic properties along with dose and adverse effects. : Conclusion and relevance of this review focus on the drugs that can be tried for the PD patients with SAR CoV-2 infection, in particular, Amantadine approved by all developed countries a common drug possessing both antiviral properties by downregulation of CTSL, lysosomal pathway disturbance and change in pH necessary to uncoat the viral proteins and antiParkinson properties. The significant prognostic adverse effect of SARS-CoV-2 on PD and the present-day treatment options, clinical presentation and various mechanism is warrant need of the hour.

Reaction Mechanisms of Inorganic and Organometallic Systems

2007 ◽  
Author(s):  
Robert B. Jordan
Keyword(s):  
Electron Transfer ◽  
Heterogeneous Systems ◽  
Asymmetric Hydrogenation ◽  
Pressure Effects ◽  
General Level ◽  
Hydrogenation Catalysts ◽  
Methyl Transferase ◽  
Transfer Region ◽  
Previous Edition ◽  
Oxide Synthase

This third edition retains the general level and scope of earlier editions, but has been substantially updated with over 900 new references covering the literature through 2005, and 140 more pages of text than the previous edition. In addition to the general updating of materials, there is new or greatly expanded coverage of topics such as Curtin-Hammett conditions, pressure effects, metal hydrides and asymmetric hydrogenation catalysts, the inverted electron-transfer region, intervalence electron transfer, photochemistry of metal carbonyls, methyl transferase and nitric oxide synthase. The new chapter on heterogeneous systems introduces the basic background to this industrially important area. The emphasis is on inorganic examples of gas/liquid and gas/liquid/solid systems and methods of determining heterogeneity.

PA.150 ANALYSIS OF THIOPURINE-METHYL-TRANSFERASE (TPMT) GENOTYPE AND PHENOTYPE IN A NORTHERN ITALIAN POPULATION

2008 ◽  
Vol 40 ◽  
pp. S130
Author(s):  
A. Vernetto ◽  
R. Sostegni ◽  
R. Canaparo ◽  
M. Daperno ◽  
L. Serpe ◽  
...  
Keyword(s):  
Italian Population ◽  
Methyl Transferase

scholarly journals THU0410 COMPANION IMMUNOSUPPRESSION WITH AZATHIOPRINE INCREASES THE FREQUENCY OF PERSISTENT RESPONSIVENESS TO PEGLOTICASE IN PATIENTS WITH CHRONIC REFRACTORY GOUT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 442.2-443 ◽  
Author(s):  
H. Rainey ◽  
H. S. B. Baraf ◽  
A. Yeo ◽  
P. Lipsky
Keyword(s):  
Serum Urate ◽  
Infusion Reaction ◽  
Blood Levels ◽  
Open Label ◽  
Methyl Transferase ◽  
The Us ◽  
The Mean ◽  
Artery Disease ◽  
Metabolizing Enzyme ◽  
Gout Flares

Background:Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory gout and causes profound reductions in serum urate. However, treatment with pegloticase is limited by the induction of anti-drug antibodies and loss of responsiveness in nearly half of treated patients.Objectives:The goal of this study was to determine whether co-therapy with azathioprine (AZA) would increase the frequency of chronic refractory gout patients who had persistent urate lowering from pegloticase therapy.Methods:This open label multicenter study enrolled subjects with chronic gout who failed to lower serum urate to <6 mg/dL despite medically indicated doses of urate lowering therapy (NCT02598596). Patients were screened for adequate levels of the AZA metabolizing enzyme thiopurine methyl transferase and then started on daily oral AZA 1.25 mg/kg for 1 week and then 2.5 mg/kg for the remainder of the trial. Blood levels of AZA metabolites 6-thioguanine and 6-methylmercaptopurine were measured biweekly. After receiving 2 weeks of AZA, patients were started on pegloticase (8 mg IV) and were treated biweekly for 24 weeks. The primary endpoint was the persistent lowering of serum urate to <6 mg/dL at the last three consecutive study visits. Patients who had an increase in serum urate to >6 mg/dL while on therapy did not receive additional pegloticase. All patients received infusion prophylaxis with hydrocortisone as well as gout flare prophylaxis.Results:To date, 12 patients have been enrolled. All patients were male, 75% white and 25% African American. Mean age was 62.4 ± 14.7 years, the mean BMI was 31.1 ± 4.5 and the mean duration of gout was 13.8 ± 9.2 years. At baseline, all patients had visible tophi; 58.3% suffered from gout flares; 81.8% had hypertension; 45.5% had dyslipidemia and 9.0% had coronary artery disease. Of the 12 patients, 6 have completed the full course of treatment with persistent urate lowering and 2 remain on treatment also with persistent urate lowering (figure). 2 patients lost the urate lowering effect, both after 2 doses of pegloticase, and did not receive additional therapy. 1 patient experienced an infusion reaction during the first dose (1 infusion reaction in 90 infusions [1.1%] in the entire trial to date) and 1 subject had subjective symptoms of AZA intolerance with no laboratory abnormalities; these subjects discontinued the study and were not evaluable for the endpoint. No adverse events related to AZA were reported and gout flares were noted in 6 subjects (mean 1.5 flares/patient with flares).Conclusion:AZA can be used safely in subjects with chronic refractory gout and appears to increase the frequency of subjects experiencing long term lowering of serum urate.References:Disclosure of Interests: :Hope Rainey: None declared, Herbert S.B. Baraf Grant/research support from: Horizon; Gilead Sciences, Inc.; Pfizer; Janssen; AbbVie, Consultant of: Horizon; Gilead Sciences, Inc.; Merck; AbbVie, Speakers bureau: Horizon, Anthony Yeo Employee of: Horizon, Peter Lipsky Consultant of: Horizon Therapeutics

Sign in / Sign up

Export Citation Format

Share Document